Search research articles
Contact Us
Filters
Showing results (31-40 of 42) with videos related to
Page
of 5
Sort By:
Diagnostics (Basel, Switzerland)
|
March 25, 2022
Detection of <i>NTRK</i> Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based Cohort
Bart Koopman, Chantal C H J Kuijpers, Harry J M Groen, et al.
Macromolecular Bioscience
|
September 4, 2015
Mold-Based Application of Laser-Induced Periodic Surface Structures (LIPSS) on Biomaterials for Nanoscale Patterning
Wim Hendrikson, Wendy Masman-Bakker, Bas van Bochove, et al.
Histopathology
|
January 7, 2021
Non-small-cell lung cancer infiltrated with chronic myelomonocytic leukaemia: a molecular diagnostic challenge to recognise mixed cancers in a single biopsy
Bart Koopman, Birgitta I Hiddinga, Inge Platteel, et al.
European Journal of Haematology
|
October 23, 2025
Clonal Progression and Leukemic Transformation of a TP53 Mutated Post-Polycythaemia Vera Myelofibrosis
Isidor Minović, Bart Koopman, Joris J W Ploegmakers, et al.
Respiratory Medicine
|
April 6, 2024
Organ involvement in newly diagnosed sarcoidosis patients in the Netherlands: The first large European multicentre prospective study
Julie Van Woensel, Bart Koopman, Mart Schiefer, et al.
Cancer Science
|
October 11, 2020
Association of homozygous variants of STING1 with outcome in human cervical cancer
Joyce M Lubbers, Bart Koopman, Jessica M de Klerk-Sluis, et al.
Cancers
|
July 24, 2021
A Nationwide Study on the Impact of Routine Testing for <i>EGFR</i> Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on <i>EGFR</i> Mutation Subclasses
Bart Koopman, Betzabel N Cajiao Garcia, Chantal C H J Kuijpers, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 15, 2020
Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation
Pei Meng, Bart Koopman, Klaas Kok, et al.
JCO Precision Oncology
|
January 20, 2022
Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non-Small-Cell Lung Cancer With Rare or Complex Mutational Profiles
Bart Koopman, Anthonie J van der Wekken, Arja Ter Elst, et al.
Clinical Lung Cancer
|
July 30, 2021
Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature
Bart Koopman, Harry J M Groen, Ed Schuuring, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 42) with videos related to
Sort By:
Page
of 5
Diagnostics (Basel, Switzerland)
|
March 25, 2022
Detection of <i>NTRK</i> Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based Cohort
Bart Koopman, Chantal C H J Kuijpers, Harry J M Groen, et al.
Macromolecular Bioscience
|
September 4, 2015
Mold-Based Application of Laser-Induced Periodic Surface Structures (LIPSS) on Biomaterials for Nanoscale Patterning
Wim Hendrikson, Wendy Masman-Bakker, Bas van Bochove, et al.
Histopathology
|
January 7, 2021
Non-small-cell lung cancer infiltrated with chronic myelomonocytic leukaemia: a molecular diagnostic challenge to recognise mixed cancers in a single biopsy
Bart Koopman, Birgitta I Hiddinga, Inge Platteel, et al.
European Journal of Haematology
|
October 23, 2025
Clonal Progression and Leukemic Transformation of a TP53 Mutated Post-Polycythaemia Vera Myelofibrosis
Isidor Minović, Bart Koopman, Joris J W Ploegmakers, et al.
Respiratory Medicine
|
April 6, 2024
Organ involvement in newly diagnosed sarcoidosis patients in the Netherlands: The first large European multicentre prospective study
Julie Van Woensel, Bart Koopman, Mart Schiefer, et al.
Cancer Science
|
October 11, 2020
Association of homozygous variants of STING1 with outcome in human cervical cancer
Joyce M Lubbers, Bart Koopman, Jessica M de Klerk-Sluis, et al.
Cancers
|
July 24, 2021
A Nationwide Study on the Impact of Routine Testing for <i>EGFR</i> Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on <i>EGFR</i> Mutation Subclasses
Bart Koopman, Betzabel N Cajiao Garcia, Chantal C H J Kuijpers, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 15, 2020
Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation
Pei Meng, Bart Koopman, Klaas Kok, et al.
JCO Precision Oncology
|
January 20, 2022
Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non-Small-Cell Lung Cancer With Rare or Complex Mutational Profiles
Bart Koopman, Anthonie J van der Wekken, Arja Ter Elst, et al.
Clinical Lung Cancer
|
July 30, 2021
Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature
Bart Koopman, Harry J M Groen, Ed Schuuring, et al.
Page
of 5